GlassScriptPhysician profile
Edward Mostel
NPI 1710921143
$6,841.17
in general payments reported to CMS, 2019-2025
43 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $354 · 2021: $1,020 · 2022: $1,037 · 2023: $1,060 · 2024: $1,303 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,662 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,661.69 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,625.69 | 2019-2025 | |
| Amgen INC. | $537.22 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $453.63 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $423.36 | 2019-2025 | Watchman Flx, Opticross, Watchman Access System |
| Merck Sharp & Dohme LLC | $364.72 | 2021-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $341.93 | 2019-2024 | Amplatzer Amulet |
| Pfizer INC. | $335.52 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $312.28 | 2019-2025 | Farxiga |
| Penumbra, INC. | $305.87 | 2024-2025 | Indigo System, Penumbra System |
| E.R. Squibb & Sons, L.L.C. | $283.93 | 2019-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $151.99 | 2021-2023 | Reveal Linq, Venaseal |
| Esperion Therapeutics, INC. | $144.87 | 2020-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $142.14 | 2021-2025 | |
| Kestra Medical Technology Services, INC. | $136.03 | 2024-2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $116.82 | 2023-2025 | Lifevest |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.54 | 2021-2023 | Jardiance |
| Philips North America LLC | $107.25 | 2019-2024 | (Br5) Peripheral Ivus |
| Alnylam Pharmaceuticals INC. | $105.04 | 2022-2025 | Onpattro |
| Abiomed | $76.40 | 2024-2025 | Impella |
| Cardiovascular Systems INC. | $75.95 | 2019-2023 | Diamondback Coronary |
| Chiesi USA, INC. | $72.85 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $70.41 | 2021-2023 | Opsumit |
| Sanofi-Aventis U.S. LLC | $58.84 | 2023-2024 | |
| Novo Nordisk INC | $45.31 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Inari Medical, INC. | $43.69 | 2022 | |
| Agepha Pharma Fz LLC | $42.72 | 2024-2025 | Lodoco |
| Amarin Pharma, INC. | $34.74 | 2021 | |
| Cvrx, INC. | $33.99 | 2024 | Barostim Neo System |
| Scpharmaceuticals INC. | $27.41 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $26.51 | 2021 | |
| Heartflow, INC. | $23.71 | 2023 | Ffrct |
| Tactile Systems Technology INC | $23.32 | 2025 | Nimbl, Flexitouch Plus |
| Cleerly, INC. | $22.72 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Kiniksa Pharmaceuticals, LTD. | $21.07 | 2023 | Arcalyst |
| Lundbeck LLC | $19.47 | 2019 | |
| Amryt Pharma Holdings LTD | $18.32 | 2021 | |
| Lilly USA, LLC | $17.00 | 2025 | Zepbound |
| Silk Road Medical, INC. | $16.66 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.61 | 2021 | |
| Medtronic Vascular, INC. | $15.66 | 2019 | |
| Zoll Circulation INC | $15.00 | 2022 | |
| Angiodynamics, INC. | $12.95 | 2021 | |
| Cardiva Medical, INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Mostel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.